Maze Therapeutics, Inc.
MAZE
Rank in Stocks
#6021
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops... Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Share Price
$34.91
Last synced: 2026-11-09
Market Cap
$1.94B
Change (1 day)
2.11%
Change (1 year)
7.22%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Maze Therapeutics, Inc. (MAZE)
Category
Healthcare
Operating Margin for Maze Therapeutics, Inc. (MAZE)
Operating Margin as of November 2026 TTM: -728.06%
According to Maze Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -728.06%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Maze Therapeutics, Inc. from 2022 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -728.06% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | 34.38% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.05% |
US
|
|
| -149.01% | -99.80% |
US
|
|
| 25.57% | -100.04% |
AU
|
|
| 31.23% | -100.04% |
BE
|
|
| 29.35% | -100.04% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Maze Therapeutics, Inc.'s operating margin
What is Maze Therapeutics, Inc.'s operating margin?
Maze Therapeutics, Inc.'s operating margin is -728.06%, as of Nov 2026.
What was Maze Therapeutics, Inc.'s operating margin in 2025?
In 2025, Maze Therapeutics, Inc.'s operating margin was 0.00%, compared with 34.38% in 2024.
How has Maze Therapeutics, Inc.'s operating margin changed since 2022?
From 2022 to 2025, Maze Therapeutics, Inc.'s operating margin was highest in 2024 (34.38%) and lowest in 2025 (0.00%).
How does Maze Therapeutics, Inc.'s operating margin compare with similar companies?
Maze Therapeutics, Inc.'s operating margin (-728.06%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.